{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T07:53:20Z","timestamp":1758268400042,"version":"3.40.4"},"reference-count":5,"publisher":"S. Karger AG","issue":"4-5","license":[{"start":{"date-parts":[[1998,1,1]],"date-time":"1998-01-01T00:00:00Z","timestamp":883612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[1998,1,1]],"date-time":"1998-01-01T00:00:00Z","timestamp":883612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Skin Pharmacol Physiol"],"published-print":{"date-parts":[[1998]]},"abstract":"<jats:p>Recently extracorporeal photopheresis (ECP), a new therapy involving extracorporeal activation of orally administered 8-methoxypsoralen (8-MOP), has been established for the treatment of different skin diseases. The pharmacokinetic profile of 8-MOP has been pursued in a clinical study which aimed to assess the efficacy of ECP in patients with progressive systemic sclerosis and cutaneous T-cell lymphoma. However, the enormous intraindividual variations in plasma as well as buffy coat concentrations affect the efficacy of oral 8-MOP therapy. Therefore, the introduction of a liquid 8-MOP formulation enabling the direct administration of the drug into the treatment bag of the ECP device is challenging.<\/jats:p>","DOI":"10.1159\/000029835","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T17:26:45Z","timestamp":1050427605000},"page":"258-265","source":"Crossref","is-referenced-by-count":4,"title":["Drug Monitoring of Orally Administered 8-Methoxypsoralen in Patients Treated with Extracorporeal Photopheresis"],"prefix":"10.1159","volume":"11","author":[{"given":"A.","family":"Balogh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Looks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Vollandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Wollina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[1999,1,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(87)90190-0"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(87)90183-3"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.126.10.1369"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(83)90055-4"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(79)90060-3"}],"container-title":["Skin Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/29835","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/29835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:27:35Z","timestamp":1745468855000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000029835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998]]},"references-count":5,"journal-issue":{"issue":"4-5","published-online":{"date-parts":[[1998,10,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000029835","archive":["Portico"],"relation":{},"ISSN":["1660-5527","1660-5535"],"issn-type":[{"type":"print","value":"1660-5527"},{"type":"electronic","value":"1660-5535"}],"subject":[],"published":{"date-parts":[[1998]]}}}